In cervical cancer, TROP2 levels were associated with increased intratumoral tumor-infiltrating lymphocytes and programmed cell death-ligand 1 (PD-L1) expression.4 Conversely, TROP2/TACSTD2-high tumors had lower gene expression of immune cell markers in breast and non–small cell lung cancer,5,6 and were independently associated with poor response to immune checkpoint inhibitors (ICIs).6 These results highlight tumor-type differences in the TROP2-mediated immune landscape. Here, TACSTD2 is linked to neoplasm.